1.3M XNYS Volume
XNYS 17 Mar, 2025 5:30 PM (EDT)
Takeda Pharmaceutical Co -... Key Metrics
Select
All financials are in JPY Million and price data in USD
VIEW MORE
High Financial Strength
Mid Valuation
Technically Neutral
Mid-range Performer
These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest.
View Similar
Embed DVM
Takeda Pharmaceutical Co -... Stock Price Analysis
Day Price Range | 15.2 (LTP) 1515.2 LowHigh |
Week Price Range | 15.2 (LTP) 14.815.2 LowHigh |
Month Price Range | 15.2 (LTP) 13.715.2 LowHigh |
52 Week Price Range | 15.2 (LTP) 12.615.2 LowHigh |
Takeda Pharmaceutical Co -... Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Hit
Takeda Pharmaceutical Co - ADR's Revenue was higher than average estimate 3 times in past 3 years
EPS forecast
Current EPS
Avg. Estimate
Miss
EPS is expected to reduce by 6.7% in FY25
Consensus Recommendation
4 ANALYST Recommendations
BUY
The consensus recommendation from 4 analysts for Takeda Pharmaceutical Co - ADR is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Takeda Pharmaceutical Co -... Stock Analysis
Takeda Pharmaceutical Co -... stock analysis with key metrics, changes, and trends.
Takeda Pharmaceutical Co -... Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $4,263,762 M | 5.87% | positive |
| |
Annual Net Profit | $144,067 M | 54.56% | negative |
| |
Price to Earning Ratio | 34.24 | - | negative |
| |
Stock Price | $15.18 | 4.91% | negative |
| |
Quarterly Revenue | $1,144,124 M | 2.96% | positive |
| |
Quarterly Net profit | $23,789 M | 77.5% | negative |
| |
Debt to Equity Ratio | 0.67 | - | positive |
| |
Return on Equity(ROE) | 2.11 % | 2.11% | negative |
| |
Mutual Fund Holding | 1.15 % | -0.04% | negative |
| |
Interest Coverage Ratio | 1.44 | - | neutral |
| |
Institutional Holding | 2.32 % | -0.1% | negative |
|
Loading data..
Takeda Pharmaceutical Co - ADR - Company Profile
What does Takeda Pharmaceutical Co - ADR do?
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Takeda Pharmaceutical Co - ADR Management structure
All Gross Remunerations are in JPY
Takeda Pharmaceutical Co - ADR Board of directors
All Gross Remunerations are in JPY